Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China-Reference-Cited by-同舟云学术

Cost-effectiveness of Capecitabine + Irinotecan Versus Leucovorin + Fluorouracil + Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China

Published:2020-11 Issue:11 Volume:42 Page:2148-2158.e2
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Wu Qiuji,Zhang Pengfei,Wang Xinyuan,Zhang Mengxi,Liao Weiting,Li Qiu

Funder

National Natural Science Foundation of China

Department of Science and Technology of Sichuan Province

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference32 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Predictors of survival in stage IV metastatic colorectal cancer;Zacharakis;Anticancer Res,2010

3. Metastatic colorectal cancer-past, progress and future;Field;World J Gastroenterol,2007

4. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study;Tournigand;J Clin Oncol,2004

5. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer;Andre;GERCOR Eur J Cancer,1999

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy;Journal of Cancer Research and Clinical Oncology;2024-05-28

2. The effective combination therapies with irinotecan for colorectal cancer;Frontiers in Pharmacology;2024-02-05

3. Cost‐effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer;Cancer Medicine;2024-01

4. Cost-effectiveness analysis of pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer;Journal of Chemotherapy;2023-01-02

5. Cost–effectiveness analysis of pembrolizumab for patients with advanced esophageal cancer at PD-L1 combined positive score ≥10;Journal of Comparative Effectiveness Research;2022-10